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Hypoglycemia engenders an autonomically mediated
counterregulatory (CR)-response that stimulates
endogenous glucose production tomaintain concen-
trations within an appropriate physiological range.
Although the involvement of the brain in preserving
normoglycemia has been established, the neurocir-
cuitry underlying centrally mediated CR-responses
remains unclear. Here we demonstrate that lateral
parabrachial nucleus cholecystokinin (CCKLPBN)
neurons are a population of glucose-sensing cells
(glucose inhibited) with counterregulatory capacity.
Furthermore, we reveal that steroidogenic-factor
1 (SF1)-expressing neurons of the ventromedial nu-
cleus of the hypothalamus (SF1VMH) are the specific
target of CCKLPBN glucoregulatory neurons. This
discrete CCKLPBN/SF1VMH neurocircuit is both
necessary and sufficient for the induction of CR-
responses. Together, these data identify CCKLPBN
neurons, and specifically CCK neuropeptide, as glu-
coregulatory and provide significant insight into the
homeostatic mechanisms controlling CR-responses
to hypoglycemia.
INTRODUCTION
Due to the serious pathophysiological consequences of low
blood glucose, normoglycemia is a tightly defended state regu-
lated by a conserved and coordinated network of peripheral
and central systems. Sensory information from peripheral gluco-
sensors is integrated into the wider glucoregulatory/sensory
circuitry, defined principally by the brainstem and hypothalamus,
which in turn engages the sympathetic nervous system (SNS)1030 Cell Metabolism 20, 1030–1037, December 2, 2014 ª2014 Elseand hypothalamic-pituitary-adrenal axis to stimulate glucose
production and inhibit glucose uptake (Marty et al., 2007). Yet,
it is unclear how these disparate structures converge to orches-
trate sensorimotor responses to dysglycemia.
The lateral parabrachial nucleus (LPBN) forms part of the pre-
autonomic circuitry that subserves physiological responses to
numerous viscerosensory modalities, including nociception
(Hermanson et al., 1998), thermostasis (Nakamura andMorrison,
2008), malaise (Carter et al., 2013), and energy homeostasis (Wu
et al., 2012). As an assimilatory interoceptive relay for ascending
sensory information, the LPBN is therefore neuroanatomically
positioned to respond to various aspects of homeostatic dysre-
gulation (Saper, 2002). Indeed, the LPBN has been implicated in
responses to hypoglycemia (Briski, 1999; Fujiwara et al., 1988;
Ritter and Dinh, 1994), but detailed characterization has hitherto
been lacking.RESULTS AND DISCUSSION
CCKLPBN Neurons Are Responsive to CR-Stimuli
The functional diversity of the LPBN is underscored by a com-
plex anatomical substructure and neurochemical composition
(Fulwiler and Saper, 1984). To determine regions of hypogly-
cemic responsiveness, glucoprivation was pharmacologically
induced through administration of the glucose anti-metabolite
2-deoxyglucose (2DG) or insulin (INS) and cFOS-immunoreac-
tivty (IR), a molecular correlate of neuronal activation, assessed
across the rostral-caudal extent of the LPBN. Both stimuli
increased LPBN cFOS-IR, although the distribution and number
of activated neurons was greater upon 2DG administration (Fig-
ure 1A–1D; Figure S1 available online). Of particular note was
the common induction of cFOS-IR within the superior LPBN
(sLPBN) (Figures 1A–1C and 1E). The neuropeptide CCK is highly
expressed within the sLPBN (Fulwiler and Saper, 1985), visual-
ized here using a CCK-ires-Cre::R26-loxSTOPlox-L10-GFP line
(Figures 1F and 1G). 2DG and INS treatment significantlyvier Inc.
Figure 1. CCKLPBN Neurons Are Activated by Glucoprivation
(A–D) 2DG- and INS-induced glucoprivation promoted cFOS-IR (red) within the LPBN, as compared to saline controls. Both glucoprivic stimuli elicited cFOS-IR
within the sLPBN (B,C), with 2DG also increasing neural activity within the external compartment of the LPBN (B).
(D) Quantification of cFOS-IR across the rostral-to-caudal extent of the LPBN (see Figure S1) revealed a significant elevation of cFOS-IR in 2DG- and INS-treated
mice above saline controls (n = 3–5 per group; one-way ANOVA, F(2,8) = 31.1, p = 0.0002 with Tukey’s post hoc comparison).
(E–G) The sLPBN is located at the rostral and dorsal extreme of the LPBN and defined by the expression of CCK.
(F and G) Transgenic labeling of CCK neurons (green) in aCCK-ires-Cre::R26-loxSTOPlox-L10-GFPmouse line recapitulated the known endogenous expression
profile.
(H–K) 2DG- and INS-induced glucoprivation increased cFOS-IR (red) within CCKLPBN neurons (green) compared to saline controls (white arrows denote colo-
calized neurons) (n = 3–5 per group; one-way ANOVA, F(2,9) = 23.2, p = 0.0003 with Tukey’s post hoc comparison).
(L–N) A subset of CCKLPBN neurons were inhibited by glucose.
(L and M) 5/14 CCKLPBN neurons exhibited reversible membrane depolarization in response to a downward glucose step form 5 mM to 0.5 mM (n = 5, repeated-
measures one-way ANOVA, F(2,4) = 77.3, p = 0.0003 with Tukey’s post hoc comparison).
(N) Representative electrophysiological trace from a spontaneously active glucose-inhibited CCKLPBN neuron.
2DG, 2-deoxyglucose; e, external LPBN; INS, insulin; SAL, saline; scp, superior cerebellar peduncle; s, superior LPBN. All data are presented as mean ± SEM.
**p < 0.01; ***p < 0.001.
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Figure 2. CCKLPBN Neurons Promote SNS-
Mediated CR-Like Responses
(A and B) Bilateral stereotaxic injection of Cre-
dependent excitatory hM3Dq-mCherry virus into
the LPBN of male CCK-ires-Cre mice facilitated
real-time activation of CCKLPBN neurons.
(A) Representative image of Cre-dependent
expression of hM3Dq-mCherry specifically within
the LPBN of a CCK-ires-Cre mouse.
(B) Membrane potential and firing rate of CCK-
ires-Cre::hM3Dq-mCherry
LPBN neurons increased
upon 5 mM CNO application.
(C) CCK-ires-Cre::hM3Dq-mCherry
LPBN mice ex-
hibited a significant hyperglycemic response to
CNO, compared to saline, administration (n = 7;
repeated-measures ANOVA, main effect of treat-
ment [F(1,36) = 39.6, p < 0.0001], main effect of time
[F(5,36) = 6.6, p = 0.0002], and interaction [F(5,36) =
4.3, p = 0.003]; post hoc comparisons determined
by Sidak’s post hoc test for individual time point
analysis).
(D–F) CNO treatment evoked an increase in serum
glucagon (D; n = 3 per group; t test, t(4) = 26.0, p <
0.0001), corticosterone (E; n = 3 to 4 per group;
t test, t(6) = 4.4, p = 0.004), and epinephrine con-
centrations (F; n = 6–8 per group; t test, t(12) = 2.3,
p = 0.04).
(G) CCKLPBN neuron activation was associated
with increased hepatic G6pc mRNA expression
(n = 3 to 4 per group; t test, t(4) = 2.7, p = 0.05)
compared to saline controls.
(H) CNO-induced hyperglycemia was abolished
by pretreatment with pan-specific CCK-receptor
antagonist (20 mg/kg proglumide: PROG) (data
shown at 60 min after CNO/SAL administration;
n = 5; repeated-measures ANOVA, F(4,12) = 5.0,
p = 0.04 with Tukey’s post hoc comparison).
(I and J) CNO treatment did not influence feeding
behavior compared to saline. (I) Three hour dark-
cycle food intake (n = 10; paired t test, t(9) = 0.4, p =
0.7) and (J) 3 hr light-cycle food intake (n = 5;
paired t test, t(4) = 1.8, p = 0.1) in ad-libitum-fed
mice.
CNO, clozapine-N-oxide; G6pc, glucose-6-phos-
phatase; scp, superior cerebellar peduncle; SAL,
saline. All data are presented as mean ± SEM;
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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This identifies CCKLPBN neurons as one neurochemically defined
subpopulation of LPBN cells responsive to states of glucopriva-
tion, in addition to other non-CCK-expressing cells. To determine
the proximal glucoprivic stimulus to which CCKLPBN neurons
are responsive, we assessed their capacity to sense shifts in
extracellular glucose concentration. Whole-cell recordings from
transgenically labeled CCKLPBN neurons demonstrated that a
downward step from5mM to 0.5mM resulted in reversiblemem-
brane depolarization in 5/14 cells and in spontaneously firing
cells an increase in action potential firing rate (Figures 1L–1N;
responding cells defined by a poststimulus response greater
than 23SD±mean of recorded baseline), establishing these cells
as a population of glucose-inhibited neurons.1032 Cell Metabolism 20, 1030–1037, December 2, 2014 ª2014 ElseCCKLPBN Neuron Activation Induces CR-Like Responses
To probe the relevance of CCKLPBN neurons to glucoregulation, a
chemogenetic interrogation of their physiological function using
Designer Receptors Activated by Designer Drugs (DREADD)
(Alexander et al., 2009) was undertaken. Cre-dependent viral
transduction of CCKLPBN neurons with stimulatory hM3Dq-
mCherry facilitated robust activation in response to the designer
drug clozapine-N-oxide (CNO), as determined by ex vivo slice
electrophysiology (Figures 2A and 2B) and in vivo cFOS-IR
(Figures S2A and S2B). In freely behaving animals, CCK-ires-
Cre::hM3Dq-mCherry
LPBN neuron activation prompted an in-
crease in blood glucose concentration that reached a maximal
elevation above baseline by 60 min (Figure 2C) (CNO adminis-
tration had no effect on blood glucose concentration in thevier Inc.
Figure 3. CCKLPBN Neurons Are Necessary
for CR-Response to Glucoprivation
(A and B) Bilateral stereotaxic injection of Cre-
dependent inhibitory hM4Di-mCherry virus into
the LPBN of male CCK-ires-Cre mice facilitated
the real-time inhibition of CCKLPBN neurons.
(A) Representative image of Cre-dependent
expression of hM4Di-mCherry specifically within
the LPBN of a CCK-ires-Cre mouse.
(B) Membrane potential and firing rate of CCK-
ires-Cre::hM4Di-mCherryLPBN neurons decreased
upon 5 mM CNO application.
(C) CNO-induced CCKLPBN neuron silencing in nor-
moglycemic CCK-ires-Cre::hM4Di-mCherry
LPBN
mice had no effect on blood glucose levels, com-
pared to saline controls (n = 11; repeated-mea-
sures ANOVA, main effects of treatment and time,
and interaction, not significant).
(D and E) CNO-induced CCKLPBN neuron silenc-
ing under glucoprivic conditions attenuated the
CR-response.
(D) 2DG-induced CR was significantly diminished
by CNO pretreatment compared to saline (n = 8;
repeated-measures ANOVA, main effect of treat-
ment [F(1,49) = 14.3, p < 0.0004], main effect of
time [F(6,49) = 64.7, p < 0.0001], and interaction
[F(6,49) = 2.8, p = 0.02]; post hoc comparisons
determined by Sidak’s post hoc test for individual
time point analysis).
(E) Likewise, INS-induced CR was significantly
diminished by CNO pretreatment compared to
saline (n = 5; repeated-measures ANOVA, main
effect of treatment [F(1,32) = 4.6, p = 0.04], main
effect of time [F(7,32) = 22.3, p < 0.0001], and
interaction [F(7,32) = 2.8, p = 0.02]; post hoc com-
parisons determined by Sidak’s post hoc test for
individual time point analysis).
Abbreviations: 2DG, 2-deoxyglucose; INS, insulin;
scp, superior cerebellar peduncle; SAL, saline.
All data are presented as mean ± SEM.; **p < 0.01;
***p < 0.001; ****p < 0.0001.
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dent with this rise in blood glucose, CNO administration sig-
nificantly elevated serum levels of the CR hormones glucagon
and corticosterone (Figures 2D and 2E) but had no significant
effect on serum INS levels, although there was a trend toward
a decrease (Figure S2D). Furthermore, CCKLPBN neuron activa-
tion also stimulated sympathoexcitatory drive to the adrenal
glands, as indicated by increased serum epinephrine levels (Fig-
ure 2F), indicating that these cells couple to the SNS-circuitry
requisite for autonomic control of endogenous glucose pro-
duction. Consistent with these findings, mRNA levels of the
glucogenic gene glucose-6-phosphatase (G6pc) increased 2-
fold in livers of CNO-treatedCCK-ires-Cre::hM3Dq-mCherry
LPBN
mice, compared to saline controls (Figure 2G). We next inves-





the CCK-receptor antagonist proglumide abrogated the pre-
viously observed elevation in blood glucose (Figure 2H),
revealing that LPBN-derived CCK is the functionally relevant
neurotransmitter in this physiological context. These data
demonstrate that the CCKLPBN neurons, and specificallyCell MetabCCK neuropeptide, are sufficient to drive CR-like responses.
Interestingly, despite the involvement of both the LPBN
(Wu et al., 2012) and CCK (Little et al., 2005) in appetite control,
CCKLPBN neuron activation had no impact on feeding behavior
(Figures 2I, 2J, and S2E).
CCKLPBN Neurons Are Necessary for a Complete
CR-Response
This ability of CCKLPBN neurons to elevate blood glucose con-
centration, together with their responsiveness to glucoprivic
stimuli, alluded to an involvement in the CR-responses to hypo-
glycemia, wherein their activation facilitates the re-establish-
ment of normoglycemia. To address the physiological relevance
of CCKLPBN neurons to counterregulation, we investigated the
consequence of their chemogenetic inhibition within the context
of glucoprivation. Ex vivo electrophysiology demonstrated that
in the presence of CNO, CCK-ires-Cre::hM4Di-mCherry
LPBN
neurons exhibited membrane hyperpolarization and a decrease
in action potential firing (Figures 3A and 3B), establishing a
capacity to effectively silence CCKLPBN neurons. In freely
behaving normoglycemic (ad-libitum-fed) CCK-ires-Cre::hM4Di-
mCherryLPBN mice, CNO administration had no effect on bloodolism 20, 1030–1037, December 2, 2014 ª2014 Elsevier Inc. 1033
Figure 4. CCKLPBN Neurons Engage SF1VMH Neurons to Mediate CR-Responses
(A) Unilateral stereotaxic injection of Cre-dependent synpatophysin-mCherry virus into the LPBN of CCK-ires-Cre mice facilitated genetically defined tract
tracing of CCKLPBN neuron projections.
(B and C) CCKLPBN neurons send ascending projections to the ipsilateral hypothalamus, including the lateral hypothalamus (LH), dorsomedial nucleus (DMH),
and VMH.
(D) CNO-mediated activation of unilateral CCK-ires-Cre::hM3Dq-mCherryLPBN neurons evokes cFOS-IR (magenta) within ipsilateral SF1VMH neurons (green)
in CCK-ires-Cre::SF1-Cre::R26-loxSTOPlox-L10-GFP mice.
(E and F) A total of 55% (5/9) of synaptically isolated SF1VMH neurons were activated by CCK (CCK-8S, 100 nM) in ex vivo slice preparations maintained under
hypoglycemic conditions (0.5 mM glucose).
(E) Representative electrophysiological trace of a SF1VMH neuron demonstrating CCK-induced activation.
(F) CCK-responsive SF1VMH neurons exhibited a 2.5-fold increase in firing frequency over baseline upon CCK-8S administration (n = 6, paired t test, t(4) = 4.1,
p = 0.01).
(G and H) Functional occlusion of CCKLPBN neuron glucoregulation through concomitant silencing of downstream SF1VMH neurons.
(H) SF1-Cre::hM4Di-mCherry
VMH silencing prevents the CCK-ires-Cre::hM3Dq-mCherry
LPBN-mediated CR-response in CNO-treated double transduced mice,
as compared toCCK-ires-Cre::hM3Dq-mCherry
LPBN only transducedmice (n = 5 per group; twoway ANOVA, main effect of treatment [F(1,56) = 188.2, p < 0.0001],
main effect of time [F(6,56) = 11.9, p < 0.0001], and interaction [F(6,56) = 4.5, p = 0.0009]; Sidak’s post hoc test for individual time point analysis).
(legend continued on next page)
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CCKLPBN/SF1VMH Hypoglycemic Counterregulationglucose concentration (Figure 3C), revealing that these cells are
not requisite to the regulation of baseline glycemia. However,
CCKLPBN neuron silencing prior to the induction of acute gluco-
privation resulted in a significantly diminished CR-response.
Specifically, while 2DG administration prompted the expected
CR elevation in blood glucose, prior CCK-ires-Cre::hM4Di-
mCherryLPBN neuron inhibition markedly attenuated the hyper-
glycemic response (Figure 3D). Similarly, under INS-induced
hypoglycemia, CCKLPBN neuron silencing engendered an exag-
gerated hypoglycemic response that impaired re-establishment
of normoglycemia (Figure 3E). Thus, CCKLPBN neurons form part
of the neurocircuitry underlying centrally regulated glycemia and
are both necessary and sufficient for CR-responses to glucopri-
vation. CCKLPBN neuron silencing did not affect feeding behavior
(Figures S3A–S3C).
CCKLPBN Neuron-Mediated CR Requires Downstream
SF1VMH Neurons
To probe the neurocircuit underlying CCKLPBN neuron-mediated
glucoregulation, their specific efferent targets were assessed
using genetically encoded neuronal tract-tracing. Unilateral viral
transduction of CCKLPBN neurons with Cre-dependent synapto-
physin-mCherry revealed a strictly ascending projection profile,
with terminals concentrated predominantly within the ipsilateral
hypothalamus (Figures 4A–4C and S4A–S4F). The densest site
of CCKLPBN neuron innervation was the ventromedial nucleus
of the hypothalamus (VMH), and in particular the dorsomedial
compartment (dmVMH) (Figure 4C). This robust innervation,
together with the well-established glucoregulatory capacity
and preautonomic function of the VMH (Borg et al., 1994; Borg
et al., 1995; Choi et al., 2013), supported its role as a site of
functional outflow for CR CCKLPBN neurons.
SF1 is required for the terminal differentiation of the VMH and
is expressed predominantly in the dmVMH of adult mice (Choi
et al., 2013). Conditional genetic manipulations have demon-
strated that SF1 neurons are required for CR-response to hypo-
glycemia (Kim et al., 2012; Klo¨ckener et al., 2011; Tong et al.,
2007). Thus, we investigated whether SF1VMH neurons form
part of a glucoregulatory CCKLPBN/VMH microcircuit. Concor-
dant with the lateralized nature of CCKLPBN neuron projections,
unilateral CCK-ires-Cre::hM3Dq-mCherry
LPBN neuron activation
induced an increase in cFOS-IR within transgenically labeled
ipsilateral SF1VMH neurons, as compared to the contralateral
side, indicating that SF1VMH neurons lie downstream of CCKLPBN
neurons (Figure 4D). Consistent with this observation and the
excitatory effect of CCK on the VMH (Kow and Pfaff, 1986), elec-
trophysiological recordings from synaptically isolated SF1VMH
neurons at low (0.5 mM) and normal (5 mM) glucose conditions
revealed that 55% (5/9) were stimulated by exogenous CCK,
with responding cells increasing their firing rate 2.5-fold (Figures(I) SF1VMH neuron silencing does not influence blood glucose concentrations com
time, and interaction not significant).
(J) The CR-response to 2DG was significantly attenuated by pretreatment with the
main effect of treatment [F(3,112) = 369.1, p < 0.0001], main effect of time [F(6,11
comparisons determined by Tukey’s post hoc test for individual time point analy
Abbreviations: ARC, arcuate nucleus of the hypothalamus; DMH, dorsomedial
amygdaloid nucleus posterior part; PVT, paraventricular nucleus of the thalamus
ventrolateral; dm, dorsomedial. All data are presented as mean ± SEM; *p < 0.05
Cell Metab4E, 4F, and S4G); importantly, pretreatment of slices with a
CCKB-receptor antagonist (CI988) blocked responses to
CCK in all cells tested (n = 12). Non-SF1VMH neurons did not
exhibit a response to CCK (0/12 cells; Figures S4H and S4I). In
light of evidence that LPBN-derived CCK is the sole source of
CCK terminals within the VMH (Nagai et al., 1987), these data
suggest SF1VMH neuron responsiveness to CCK lies in their
innervation by CCKLPBN neurons. Furthermore, the robustly glu-
tamatergic nature of the LPBN led us to consider the potential
contribution of fast neurotransmission from CCKLPBN neurons.
Interestingly, we did not observe VMH projections from gluta-
matergic vGLUT2LPBN neurons (Figure S4J), and vGLUT2-ires-
Cre::hM3Dq-mCherryLPBN stimulation failed to elevate blood
glucose levels (Figure S4K). These data suggest that VMH-pro-
jecting CCKLPBN neurons are not glutamatergic and support
our observation that CCK receptor blockade is sufficient to
abrogate the hyperglycemic response to CNO in CCK-ires-
Cre::hM3Dq-mCherryLPBN mice (Figure 2H).
Taking advantage of the spatial exclusivity of CCK and SF1
expression in the LPBN and VMH, respectively, we next gener-
ated compound CCK-ires-Cre::SF1-Cremice to facilitate neuro-
chemically explicit manipulation of this CCKLPBN/SF1VMH
microcircuit. Specifically, we sought to functionally occlude
CCK-ires-Cre::hM3Dq-mCherry
LPBN-induced CR-responses
through the simultaneous silencing of downstream SF1-Cre::
hM4Di-mCherry
VMH neurons (Figure 4G). Concomitant CNO-
induced activation and inhibition of CCKLPBN and SF1VMH
neurons, respectively, resulted in abrogation of CCK-ires-
Cre::hM3Dq-mCherry
LPBN-mediated elevation in blood glucose
(Figure 4H). Silencing of SF1VMH neurons alone had no effect
on blood glucose concentration, indicating a causal interaction
between these two populations, and not simply a counteracting
additive effect (Figure 4I). Furthermore, like CCKLPBN neurons,
silencing of SF1VMH cells within the context of 2DG-glucopriva-
tion induced an attenuated CR-response (Figure S4L). Control
experiments performed to rule out any contribution from CCK
neurons within the dorsomedial nucleus of the hypothalamus,
compact part (cDMH), which neighbors the SF1VMH domain,
revealed that CCKcDMH neurons had neither any effect on blood
glucose levels nor were engaged by glucoregulatory CCKLPBN
neurons (Figures S4M–S4P). These data suggest that the CR
function of CCKLPBN neurons is predicated upon their engage-
ment of downstream SF1VMH neurons. Interestingly, systemic
antagonism of CCKB-receptors, the predominant central
receptor isoform (and enriched in the dmVMH), was sufficient
to significantly attenuate the hyperglycemic response to 2DG
in wild-type mice (Figure 4J), highlighting the salience of
CCKB-receptor signaling to CR-responses, although not defini-
tively identifying specific receptor-expressing neuronal
populations.pared to saline (n = 4; repeated-measures ANOVA; main effects of treatment,
selective CCKB-receptor antagonist CI988 (n = 5 per group; two-way ANOVA;
2) = 121.7, p < 0.0001], and interaction [F(18,112) = 36.2, p < 0.001]; post hoc
sis).
nucleus of the hypothalamus; LHA, lateral hypothalamic area; MeP, medial
; SAL, saline; VMH, ventromedial nucleus of the hypothalamus; c, central; vl,
; ***p < 0.001; ****p < 0.0001.
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of glucose-sensitive neurons and a requisite component of
the neurocircuitry underlying CR-responses to hypoglycemia.
Furthermore, the necessity for SF1VMH neurons as downstream
effectors of CCKLPBN-regulated glycemia befits their established
role in CR (Choi et al., 2013; Kim et al., 2012; Tong et al., 2007).
In sum, the present study defines the physiological function of
a discrete CCKLPBN/SF1VMH microcircuit that drives hepatic
glucose production and mediates CR responses to hypoglyce-
mia. Furthermore, these data identify a critical function for CCK
in the physiological response to glucoprivation. These observa-
tions have salience to both homeostatic function in health and
dysregulation in disease, in particular diabetes.EXPERIMENTAL PROCEDURES
Animals
CCK-ires-Cre (Jackson Laboratories), SF1-Cre, vGLUT2-ires-Cre, and R26-
loxSTOPlox-L10-GFP mice were generated and maintained as previously
described (Dhillon et al., 2006; Krashes et al., 2014; Taniguchi et al., 2011).
Animal care and experimental procedures were performed with approval by
the Beth Israel Deaconess Medical Center Institutional Animal Care and Use
Committee or were performed in accordance with the UK Animals (Scientific
Procedures) Act 1986.
Viruses
The DREADD viruses used have been described previously: AAV8-hSyn-DIO-
hM3Dq-mCherry and AAV8-hSyn-DIO-hM4Di-mCherry (University North Car-
olina Vector Core) (Krashes et al., 2011). A Cre-dependent expression cassette
for hEF1alpha-DIO-synaptophysin-mCherry-WPRE (Opland et al., 2013) was
generated (MIT Viral Gene Transfer Core) and the construct packaged in
AAV serotype-8 at a titer of 1.3 3 1013 vg/ml (Virovek, Inc). Nucleus specific
delivery of viruses was achieved through stereotaxic delivery based upon
coordinates defined by the Mouse Brain Atlas (Franklin and Paxinos, 2008).
Blood Glucose Studies
On test days, mice were transferred to new cages and food removed at 9:00
am. Mice remained fasted until 1:00 pm, when the experiment would
commence. Blood glucose concentration was determined by tail bleed using
a OneTouch Ultra glucometer and test strips (LifeScan, Johnson and Johnson
Company). Basal blood glucose concentration was determined prior to injec-
tion of any substances and at 15, 30, 60, 120, and 180 min postadministration.
Pretreatments were given 30 min prior to pharmacological stimulus. Experi-
ments were within study design (unless otherwise stated), with mice assessed
following saline and 1 mg/kg CNO. Animals undergoing loss-of-function ex-
periments involving glucoprivic stimuli (INS or 2DG) were counterbalanced
and given 3 weeks recovery time between treatments to ensure normal coun-
terregulatory responses were intact.
Immunohistochemistry
Brains were sectioned on a freezingmicrotome at 30 mm. Dual immunofluores-
cence histochemistry for cFOS-IR, mCherry-IR, and GFP-IR was conducted
as previously described (Garfield et al., 2012). Primary antibodies (1/1,000)
were as follows: rabbit anti-cFOS (EMD Millipore), rabbit anti-RFP (Clontech
Laboratories, Inc.), or chicken anti-GFP (EMD Millipore).
Serum and Tissue Extraction
For assessment of serum chemistry and hepatic gene expression animals
were decapitated, and fresh trunk blood and liver samples were collected.
Blood was collected in tubes containing 250 KIU/ml aprotinin (EMD Millipore),
allowed to coagulate at room temperature for 30 min, centrifuged at 1,5003 g
for 10 min, and the resulting serum transferred to a new tube. Samples were
flash frozen in liquid nitrogen and kept at 80C until analyzed. Liver extracts
were flash frozen in liquid nitrogen and kept at80C until RNAwas extracted.1036 Cell Metabolism 20, 1030–1037, December 2, 2014 ª2014 ElseElectrophysiological Studies
To assess the effects of CNO on CCKLPBN neurons, 5- to 7-week-old CCK-
ires-Cre mice were injected with either AAV8-DIO-hM3Dq-mCherry or AAV8-
DIO-hM4Di-mCherry into the LPBN 3 weeks before recording. Slices were
maintained in aCSF containing 10 mM glucose. After acquisition of stable,
whole-cell recordings for 2 to 5 min, aCSF solution containing CNO (5 mM)
was perfused into the brain slice preparation (for hM4Di-mCherry analysis,
cells were injected with 5 pA of current). To assess the effect of CCK on
VMH neurons (SF1+ or SF neurons), 6- to 8-weeks-old SF1-Cre::R26-
loxSTOPlox-L10-GFP mice were used. CCK-8S (100 nM; Tocris Biosciences)
and CI988 (500 nM; Tocris Biosciences) were applied to bath solution contain-
ing either 5 mM or 0.5 mM glucose through perfusion. After acquisition of
stable, whole-cell recording for 2–5 min, acSF solution containing 100 nM of
CCK-8S was perfused for 3 to 5 min. Synaptic blockers (1 mM kynurenate
and 100 mM picrotoxin) were added in aCSF to synaptically isolate VMH
neurons. The effect of glucose concentration on CCKLPBN neuron activity
was assessed using a 5 mM/0.5 mM/5 mM step protocol, with osmolarity
adjusted with sucrose.Statistics
Statistical analyses were performed using Prism 6 (Graphpad Software, Inc).
Data were analyzed using t test, one-way ANOVA, or two-way ANOVA
with post hoc comparisons, where appropriate. Data are presented as
mean ± SEM, and statistical significance was set at p < 0.05SUPPLEMENTAL INFORMATION
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